Filing Flows › Enanta Pharmaceuticals (ENTA) › Q1 FY26
Enanta Pharmaceuticals (ENTA) Q1 FY26 earnings results (first quarter fiscal 2026)
10-Q filed Feb 11, 2026
Enanta Pharmaceuticals (ENTA) reported revenue of $18.6M for the first quarter fiscal 2026 (Q1 FY26), +10% from a year earlier and +23% from the quarter before. Operating margin was -60.5%, net loss $11.9M (64.1% of revenue).
Enanta Pharmaceuticals, Q1 FY26: revenue $18.6M (+10% year over year), operating margin -60.5%, net loss $11.9M, operating cash flow −$11.7M. The chart follows the revenue to costs, profit and cash.
| Q1 FY26 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $18.6M | +23% | +10% |
| Operating profit | −$11.3M | — | — |
| Net earnings | −$11.9M | — | — |
| Operating cash flow | −$11.7M | — | — |
What changed
Revenue was $18.6M in Q1 FY26, up 10% year over year and up 23% from the previous quarter.
Operating costs exceeded revenue by $11.3M, an operating margin of -60.5%. Total costs fell 26% while revenue rose 10%. The quarter ended with a net loss of $11.9M, narrower than the previous quarter's $18.7M loss.
Operating cash flow was −$11.7M. Non-cash charges added back $1.2M of depreciation and amortization and $3.8M of share-based compensation. Working capital and other items used $4.8M. Capital expenditures of $143K exceeded it, leaving free cash flow of −$11.8M.
Questions
What was Enanta Pharmaceuticals' revenue in the first quarter fiscal 2026?
Enanta Pharmaceuticals (ENTA) reported revenue of $18.6M for the first quarter fiscal 2026 (Q1 FY26), +10% from a year earlier and +23% from the quarter before.
Was Enanta Pharmaceuticals profitable in the first quarter fiscal 2026?
Operating loss was $11.3M (-60.5% of revenue) and net loss $11.9M.